A strong commitment to our strategic partners, our innovative and clinically-supported product lines, and our Chromax chromium picolinate pricing policies have all contributed to the financial results for the three and nine months ended March 31, 2001. We believe that we have positioned the Company on both a cost and organizational basis to react quickly to changes and opportunities in the industry, and we expect to be profitable for all of fiscal year 2001. As we move forward, we will continue to pursue programs that will strengthen our balance sheet, while positioning ourselves to more aggressively support the market expansion of our existing products and the development of new, proprietary products. Nutrition 21, Inc. develops and markets clinically substantiated products that make a significant contribution to the health and well being of consumers. Forward-looking statements are based on the company's current expectations and are subject to market, competitive and regulatory factors and the other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission.
Actual results can differ materially.
The company makes no commitment to disclose any revisions to forward-looking statements.